Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. Issue 15 (April 2017)

• Record Type: Journal Article
• Authors: Zhong, Jian-Hong; Pan, Ling-Hui; Wang, Yan-Yan; Cucchetti, Alessandro; Yang, Tian; You, Xue-Mei; Ma, Liang; Gong, Wen-Feng; Xiang, Bang-De; Peng, Ning-Fu; Wu, Fei-Xiang; Li, Le-Qun
• Other Names: Fan. Huitao section editor.
• Is Part Of: Medicine. Volume 96:Issue 15(2017)
• Publication Date: 2017-04
• Subjects: hepatic resection -- hepatocellular carcinoma -- overall survival -- stage designation -- tumor size; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000006608
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: This study aims to refine the designation for single hepatocellular carcinoma (HCC) >5 cm by comparing the postresection prognosis of these patients with those who have a single-tumor ⩽5 cm and those with stage B. Patients with a single-tumor were classified into subgroups based on diameter. Of the 1132 patients analyzed, 426 had a single-tumor >2 and ⩽5 cm; 229, a single-tumor >5 and ⩽8 cm; 52, a single-tumor >8 and < 10 cm; 150, a single-tumor ≥10 cm; and 275, stage B. Hospital mortality and complications increased with tumor size among the single-tumor subgroups and median survival decreased with increasing of tumor size. Overall survival (OS) among patients with a single-tumor >5 cm was significantly lower than among patients with a single-tumor >2 and ⩽5 cm ( P ⩽ .001), but significantly higher than among patients with clearly stage B ( P ⩽ .001). Patients with a single-tumor >5 and ⩽8 cm showed lower OS than patients with a single-tumor >2 and ⩽5 cm ( P < .001). Patients with a single-tumor >8 and <10 cm or a single-tumor ≥10 cm showed lower OS than patients with a single-tumor >5 and ⩽8 cm ( P = .033 and .006), and similar OS to patients with stage B ( P = .323). Patients with a single-tumor >5 and ⩽8 cm may be assigned to a new stage between early and intermediate. Patients with a single-tumor >8 cm may be assigned to intermediate stage.